Clinical Trial Update: Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pharmacodynamics of SB-656933 in ulcerative colitis was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• SB-656933

Snippet

Sponsor: GlaxoSmithKline | Conditions: Colitis, Ulcerative | Phase 2 | Status: TERMINATED | Results posted: 2018-03-14